PF-06882961 (Cohorts 1 and 2) for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jan 2021: Trial registered, NCT04707313
  2. 29 Jan 2021: Trial started, NCT04707313

The trials

NCT04707313: A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

State
Completed
Phase
Phase 2
People
628 taking part
Started
29 Jan 2021
Primary completion
13 Sep 2023
Arms
PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1), PF-06882961 80 mg BID, 1-week titration (Cohort 1), PF-06882961 120 mg BID, 1-week titration (Cohort 1), PF-06882961 160 mg BID, 1-week titration (Cohort 1), PF-06882961 200 mg BID, 1-week titration (Cohort 1), PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)
Results
Posted on the registry
  1. 13 Jan 2021: Trial registered
  2. 29 Jan 2021: Trial started
  3. 11 Oct 2023: Trial completed
  4. 9 Oct 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.